10:45 PM GMT, Jul 18, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Taiho's S-1 misses Phase III endpoint
Taiho said S-1 plus cisplatin missed the primary endpoint of superior overall survival
Read the full 136 word article